The vaccine developed by AstraZeneca and Oxford University confirmed its safety and efficiency for old people on the results of the trials, as the BBC reported.
560 volunteers participated in the clinical trials; half of them were over 70 years olds. The scientists injected two doses of vaccine with intervals of two weeks or a month, estimating the response of the bodies and immunities of the volunteers of each age group to these injections. Later, the scientists collected the samples of blood and defined and the number of antibodies to SARS-CoV-2.
The results of the research showed that people at the age of 56-69 and older than 70 had stable immune reactions similar to the reactions of people at the age of 18 up to 55.
“Older people's weaker immune systems mean vaccines do not tend to function as well as they do in younger people…The next step will be to see if this translates into protection from the disease itself," Dr. Maheshi Ramasamy said.
Soon, the scientists plan to involve even older volunteers to try the vaccine, as well as people with chronic illnesses. Besides, they plan to hold the third phase of the trials with the participation of old people.
Today, the vaccine of AstraZeneca and Oxford University is considered to be one of the most promising on the market.
As we reported earlier, according to the results of the clinical trials, Moderna's vaccine against coronavirus is 94.5% effective. The trial involved 30,000 people in the US with half being given two doses of the vaccine, four weeks apart. The rest had dummy injections.
Besides, during the final stage of the trial of the vaccine against coronavirus infection developed by Pfizer and BioNTech, its efficacy was increased up to 94%.